Relevant bibliographies by topics / Ovarian cancer, chemotherapy / Dissertations / Theses
To see the other types of publications on this topic, follow the link: Ovarian cancer, chemotherapy.

Dissertations / Theses on the topic 'Ovarian cancer, chemotherapy'

Author: Grafiati
Published: 24 April 2022
Last updated: 30 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 50 dissertations / theses for your research on the topic 'Ovarian cancer, chemotherapy.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse dissertations / theses on a wide variety of disciplines and organise your bibliography correctly.

1

Newton, C. "Clinical resistance to platinum chemotherapy in ovarian cancer." Thesis, University College London (University of London), 2009. http://discovery.ucl.ac.uk/1446312/.

Full text
Abstract:
Platinum drugs are the most active agents in ovarian cancer. Their cytotoxicty results from DNA crosslinking. High tumour response rates are seen, but 80 % of patients relapse. Major mechanisms of platinum resistance in patients remain to be established. We have studied DNA interstrand crosslinking and its repair in response to ex vivo treatment with cisplatin in forty patients with ovarian cancer using the single cell gel electrophoresis (comet) assay. Tumour cells from resected tumours or tumour and mesothelial cells from ascites were obtained from chemonaive patients and those relapsing aft
APA, Harvard, Vancouver, ISO, and other styles
2

Gao, Bo. "Genetic polymorphisms and chemotherapy response in ovarian cancer." Thesis, The University of Sydney, 2014. http://hdl.handle.net/2123/12884.

Full text
Abstract:
Epithelial ovarian cancer (EOC) is usually treated with paclitaxel and carboplatin combination. Germline genetic variations may affect drug clearance therefore response. ABCB1 (ATP-binding cassette B1) is an efflux transporter of paclitaxel. We found an association between ABCB1 polymorphisms and survival in EOC patients. In lymphoblastoid cell lines (LCLs), ABCB1 expression correlated with transporter activity and paclitaxel sensitivity, but not with ABCB1 polymorphisms. In a prospective pharmacokinetic study, an association was identified between ABCB1 genotypes and paclitaxel clearance in t
APA, Harvard, Vancouver, ISO, and other styles
3

Shirai, Takako. "Primary chemotherapy patterns for ovarian cancer treatment in Japan." Kyoto University, 2010. http://hdl.handle.net/2433/120581.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Kikkawa, Fumitaka, Akihiro Nawa, Kazuhiko Ino, et al. "Advances in treatment of epithelial ovarian cancer." Nagoya University School of Medicine, 2006. http://hdl.handle.net/2237/6129.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Lo, Charlotte Sum-Yee. "Immune infiltration in ovarian cancer and its significance in chemotherapy." Thesis, University of British Columbia, 2015. http://hdl.handle.net/2429/52275.

Full text
Abstract:
High grade serous carcinoma (HGSC), the most commonly diagnosed ovarian cancer subtype, is often presented as late stage disease with high recurrence rates, thus contributing to poor prognosis. Despite poor survival outcomes, the presence of tumour-infiltrating lymphocytes (TIL) in primary, untreated tumours is associated with increased survival. However, little is known about the phenotype and composition of TIL subsets in HGSC patients following treatment. In this thesis, we investigated the functional phenotype of TIL and the changes in immune composition in tumours over the course of ch
APA, Harvard, Vancouver, ISO, and other styles
6

Bolyard, Chelsea M. "Oncolytic Virus Therapy in Combination with Chemotherapy for Ovarian Cancer." The Ohio State University, 2013. http://rave.ohiolink.edu/etdc/view?acc_num=osu1386007453.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Chowdhury, Mohd Raquibul. "Ovarian Cancer therapy combining the modalities of hyperthermia and chemotherapy." FIU Digital Commons, 2007. https://digitalcommons.fiu.edu/etd/2351.

Full text
Abstract:
Ovarian is the leading cause of deaths in women diagnosed with gynecological malignancies. Current treatments include chemotherapy which may cause severe side effects. The purpose of this study was to investigate the combinational therapeutic effect of chemotherapy and hyperthermia to an ovarian cancer cell line and compare the effects of inducing hyperthermia systemically with localized hyperthermia. Cells were seeded in 96-well plates and subjected to different doses of chemotherapy agent; Doxorubicin (DOX). To simulate systemic hyperthermia the 96-well plate was incubated for 60 minutes at
APA, Harvard, Vancouver, ISO, and other styles
8

Österberg, Lovisa. "Characterization of genetic alterations in ovarian cancer associated with chemotherapy response /." Göteborg : Department of Oncology, Institute of Clinical Sciences, The Sahlgrenska Academy at University of Gothenburg, 2009. http://hdl.handle.net/2077/20291.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Abo, Donia Mohammed Najim Abed. "Evaluation of drug combinations to sensitize ovarian cancer cells to chemotherapy." Thesis, Keele University, 2018. http://eprints.keele.ac.uk/4591/.

Full text
Abstract:
Ovarian cancer is a complex disease characterized by low incidence, accounting for about 4% of cancer diagnoses in women, but with rapid progression and higher mortality rate than any other gynecological malignancy. Approximately 70 % of the cases are diagnosed late in the course of the disease due to unawareness of subtle symptoms and failure of screening methods for detecting the disease at early-stage. Although most patients respond well to standard treatment, which involves surgery followed by platinum/taxane combination therapy, relapse seems unavoidable and the majority of patients prese
APA, Harvard, Vancouver, ISO, and other styles
10

Singh, K. J. D. L. "Ovarian reserve testing in premenopausal recipients of chemotherapy for breast cancer." Thesis, University College London (University of London), 2008. http://discovery.ucl.ac.uk/1444394/.

Full text
Abstract:
The incidence of breast cancer has progressively increased, while survival rates have simultaneously improved. Young women with breast cancer are likely to suffer ovarian damage from chemotherapy, which can have a profound effect on their quality of life. At present, it is impossible to predict the functional lifespan of the chemotherapeutically damaged ovary as there is insufficient data. Ovarian reserve tests (ORT) have the potential to estimate the reproductive age of the ovaries, which would allow an accurate estimation of fertility status and the risk of premature ovarian failure. This pr
APA, Harvard, Vancouver, ISO, and other styles
11

Gilmore, Paula. "The identification of novel genes involved in chemotherapy resistance in ovarian cancer." Thesis, Queen's University Belfast, 1997. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.361248.

Full text
APA, Harvard, Vancouver, ISO, and other styles
12

Song, Emma Yanjun Clinical School St George Hospital Faculty of Medicine UNSW. "Targeted alpha therapy for epithelial ovarian cancer." Awarded by:University of New South Wales. Clinical School - St George Hospital, 2007. http://handle.unsw.edu.au/1959.4/40874.

Full text
Abstract:
Purpose: Control of micrometastatic ovarian cancer in the peritoneal cavity remains a major objective in post-surgical treatment. The purpose of this project was to investigate the efficacy and toxicity of targeted alpha therapy (TAT) for ovarian cancer in vitro and in vivo in animal models and to select the optimal targeting vector for an ovarian cancer clinical trial. Animal models of ovarian, breast and prostate cancer were developed and for further TAT; a phase I melanoma clinical trial was supported, paving the way for an ovarian cancer clinical trial. Methods: The expression of the turn
APA, Harvard, Vancouver, ISO, and other styles
13

Weaver, Andrew. "Dose intensive chemotherapy in ovarian cancer and the role of stem cell factor." Thesis, Imperial College London, 1998. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.287931.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Roncolato, Felicia. "Improving prognostication and decision-making about chemotherapy in women with recurrent ovarian cancer." Thesis, The University of Sydney, 2018. http://hdl.handle.net/2123/19221.

Full text
Abstract:
The aim of this thesis was to improve oncologists’ ability to prognosticate and select women with recurrent ovarian cancer (ROC) for further chemotherapy using information based on their symptoms, signs, psychosocial characteristics, and laboratory results. Women with ROC are a heterogeneous group of patients - some respond to chemotherapy, others have rapid disease progression despite chemotherapy and die. Identifying who might benefit from chemotherapy is a clinical challenge. Using data from the Gynecologic Cancer InterGroup Symptom Benefit Study (N=948) which enrolled women with plati
APA, Harvard, Vancouver, ISO, and other styles
15

Fantozzi, Giulia. "Influence of centrosome amplification on the response to chemotherapy in epithelial ovarian cancer." Electronic Thesis or Diss., Université Paris sciences et lettres, 2023. http://www.theses.fr/2023UPSLS058.

Full text
Abstract:
Le cancer épithélial de l’ovaire (CEO) est l’une des principales causes de décès par cancer chez la femme, en raison d’un diagnostic souvent tardif. Le traitement de première intention consiste en une chirurgie, suivie d’une combinaison de paclitaxel et de carboplatine comme chimiothérapie. Malgré une réponse initiale à ces traitements chez 80 % des patientes, malheureusement 70 % d’entre elles vont présenter une récidive. Le centrosome est le principal centre organisateur des microtubules dans les cellules animales. Il contribue à la division cellulaire, à la migration et à l’invasion. L’ampl
APA, Harvard, Vancouver, ISO, and other styles
16

Aswad, Saad Ghazal. "The clinical and cellular pharmacology of carboplatin in relation to toxicity and response in epithelial ovarian cancer." Thesis, University of Newcastle Upon Tyne, 1994. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.241070.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Hess, Lisa M. "Pilot Study of Patient and Oncologist Preferences for Chemotherapy Treatment of Advanced Ovarian Cancer." Diss., The University of Arizona, 2007. http://hdl.handle.net/10150/196055.

Full text
Abstract:
Ovarian cancer is the leading cause of gynecologic cancer death among women in the United States, claiming the lives of more than 15,000 women each year. Women who receive this diagnosis must make rapid, critical medical decisions that impact survival and quality of life. Two studies were conducted to obtain pilot data related to the health preferences of ovarian cancer patients and their oncologists. Forty-one eligible patients and 34 eligible physicians participated in this study. Six hypothetical health states were developed based on possible outcomes of ovarian cancer treatment strategie
APA, Harvard, Vancouver, ISO, and other styles
18

ANDO, YUICHI, AKIHIRO NAWA, MASAKI SAWADA, et al. "EXTRAVASATION OF PEGYLATED-LIPOSOMAL DOXORUBICIN: FAVORABLE OUTCOME AFTER IMMEDIATE SUBCUTANEOUS ADMINISTRATION OF CORTICOSTEROIDS." Nagoya University School of Medicine, 2012. http://hdl.handle.net/2237/16037.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Hall, Jacqueline A. "Molecular markers of resistance to chemotherapy in ovarian cancer : statistical issues and study design." Thesis, University of Glasgow, 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.443427.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Datta, Shreelata. "A study to investigate the immune response in ovarian cancer patients treated with chemotherapy." Thesis, Imperial College London, 2016. http://hdl.handle.net/10044/1/57030.

Full text
Abstract:
Women with ovarian cancer usually present with advanced stage disease and, although sensitive to chemotherapy initially, the majority will relapse following first line treatment. Resistance to chemotherapy contributes to poor prognosis in ovarian cancer. A potential strategy to prolong the response to treatment and reduce chemotherapy resistance is immune based therapies. These therapies are likely to be most effective when disease is minimal or subclinical, such as at completion of first line chemotherapy, but depend on the ability to mobilize a sufficient immune response. Currently, little i
APA, Harvard, Vancouver, ISO, and other styles
21

Newton, Melissa J. "An exercise intervention for women undergoing chemotherapy for ovarian cancer : feasibility and preliminary outcomes." Thesis, Queensland University of Technology, 2010. https://eprints.qut.edu.au/45452/1/Melissa_Newton_Thesis.pdf.

Full text
Abstract:
Exercise interventions during adjuvant cancer treatment have been shown to increase functional capacity, relieve fatigue and distress and in one recent study, assist chemotherapy completion. These studies have been limited to breast, prostate or mixed cancer groups and it is not yet known if a similar intervention is even feasible among women diagnosed with ovarian cancer. Women undergoing treatment for ovarian cancer commonly have extensive pelvic surgery followed by high intensity chemotherapy. It is hypothesized that women with ovarian cancer may benefit most from a customised exercise int
APA, Harvard, Vancouver, ISO, and other styles
22

Webb, Timothy A. "Celecoxib enhances sorafenib/sildenafil lethality in cancer cells and reverts platinum chemotherapy resistance." VCU Scholars Compass, 2016. http://scholarscompass.vcu.edu/etd/4084.

Full text
Abstract:
The present studies sought to determine whether the lethality of the drug combination [sorafenib + sildenafil] could be enhanced by the anti-inflammatory agent celecoxib, using ovarian cancer and other tumor cell lines as models. Also, in a dose dependent fashion celecoxib enhanced [sorafenib + sildenafil] lethality in multiple ovarian cancer cell lines. In a dose dependent fashion celecoxib enhanced the ability of [sorafenib + sildenafil] to reduce expression of multiple chaperone proteins in parallel with lower levels of the drug efflux pumps ABCB1 and ABCG2. Over-expression of GRP78 and HSP
APA, Harvard, Vancouver, ISO, and other styles
23

Jiménez, Sánchez Alejandro. "Characterisation of the tumour microenvironment in ovarian cancer." Thesis, University of Cambridge, 2019. https://www.repository.cam.ac.uk/handle/1810/287935.

Full text
Abstract:
The tumour microenvironment comprises the non-cancerous cells present in the tumour mass (fibroblasts, endothelial, and immune cells), as well as signalling molecules and extracellular matrix. Tumour growth, invasion, metastasis, and response to therapy are influenced by the tumour microenvironment. Therefore, characterising the cellular and molecular components of the tumour microenvironment, and understanding how they influence tumour progression, represent a crucial aim for the success of cancer therapies. High-grade serous ovarian cancer provides an excellent opportunity to systematically
APA, Harvard, Vancouver, ISO, and other styles
24

Liu, Xin, and 刘昕. "Epigenetic silencing of microRNA-199b-5p leads to chemoresistance via activation of JAG1 (jagged1) in ovarian cancer." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hub.hku.hk/bib/B50533927.

Full text
Abstract:
Epithelial ovarian cancer is a leading fatal malignancy in women. The high mortality rate of this cancer is due to the poor prognosis and that the majority of patients are diagnosed at late stage. Therefore, a combination of cytoreduction and adjuvant chemotherapy is the only choice for this disease at late stage. Platinum-based chemotherapy regimens are the first line treatment for ovarian cancer. However, the repetitive challenges of platinum-based agents and the frequent relapse cause acquired chemoresistance which is the major obstacle for clinical management of this disease. The underlyi
APA, Harvard, Vancouver, ISO, and other styles
25

Carser, J. C. "The role of BRCA1 as a marker of clinical outcome following chemotherapy in sporadic ovarian cancer." Thesis, Queen's University Belfast, 2010. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.517246.

Full text
APA, Harvard, Vancouver, ISO, and other styles
26

LeitÃo, Nilza Maria de Abreu. "Assessment of health-related quality of women with cancer of women with breast and ovarian cancer in adjuvant chemotherapy Life." Universidade Federal do CearÃ, 2012. http://www.teses.ufc.br/tde_busca/arquivo.php?codArquivo=11918.

Full text
Abstract:
This research work aimed to assess the Health-Related Quality of Life of women with breast and gynecological cancer undergoing adjuvant antineoplastic chemotherapy. A descriptive study with cross-sectional design and quantitative approach. The research took place at the chemotherapy ward of a nonprofit tertiary referral hospital for cancer surgery in Fortaleza-CE, Brazil. The study sample consisted of 72 women. Data collection happened from April to May 2012. After given informed consent, all women participated in individual interviews and completed the research protocol consisting of a questi
APA, Harvard, Vancouver, ISO, and other styles
27

Manousakidi, Sevasti. "Étude des activités du FGF1 dans les tumeurs ovariennes." Thesis, Université Paris-Saclay (ComUE), 2017. http://www.theses.fr/2017SACLV049.

Full text
Abstract:
Le cancer ovarien comprend un groupe hétérogène de tumeurs pouvant affecter les cellules épithéliales, stromales ou germinales. Le traitement de ces tumeurs constitue un défi majeur car un taux important de patientes présentent une rechute suite à un traitement chimiothérapeutique. Il est donc important de comprendre les mécanismes de résistance à la chimiothérapie de ces tumeurs.Le facteur de croissance des fibroblastes 1 (FGF1) a été retrouvé surexprimé dans de nombreuses tumeurs dont les tumeurs ovariennes épithéliales de haut grade. Les études antérieures du laboratoire ont montré que le F
APA, Harvard, Vancouver, ISO, and other styles
28

Laatio, L. (Liisa). "In search of new prognostic molecular markers in ovarian cancer." Doctoral thesis, Oulun yliopisto, 2012. http://urn.fi/urn:isbn:9789514298349.

Full text
Abstract:
Abstract Ovarian cancer is the leading cause of death from gynaecological cancers in the Western world. Ovarian cancer comprises of tumours with distinct behaviour and individually different responses to chemotherapy, even within the same histology. Unfortunately, there are no molecular markers in clinical use to either distinguish between patients with better and worse prognosis or to predict individual chemosensitivity. The comprehension of the molecular effects of chemotherapeutic drugs is a prerequisite for finding predictive molecular factors for chemoresponse and prognosis. Some proteins
APA, Harvard, Vancouver, ISO, and other styles
29

Clements, Meredith L. "Chemotherapy-Induced Alopecia and Quality-of-Life: Ovarian and Uterine Cancer Patients and the Aesthetics of Disease." Scholar Commons, 2017. http://scholarcommons.usf.edu/etd/6815.

Full text
Abstract:
This study is an examination of ovarian and uterine cancer patients’ perceptions of chemotherapy-induced alopecia and how it impacts quality-of-life over the course of chemotherapy. The chapters in this dissertation address the following research questions: How do ovarian and uterine cancer patients communicate about their experiences of alopecia over the course of chemotherapy? How does chemotherapy-induced alopecia influence patients’ understandings of quality-of-life? Longitudinal interviews were conducted with a patient population of twenty-three, and each patien
APA, Harvard, Vancouver, ISO, and other styles
30

Wang, Yue, Yiying Wang, Jie Li, et al. "PAX8: a sensitive and specific marker to identify cancer cells of ovarian origin for patients prior to neoadjuvant chemotherapy." BioMed Central, 2013. http://hdl.handle.net/10150/610185.

Full text
Abstract:
BACKGROUND:Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelia
APA, Harvard, Vancouver, ISO, and other styles
31

Singh, Preetinder Pal Clinical School Prince of Wales Hospital Faculty of Medicine UNSW. "A combination of molecular and traditional chemotherapy: prospects of synergies against cancer." Awarded by:University of New South Wales. Clinical School - Prince of Wales Hospital, 2009. http://handle.unsw.edu.au/1959.4/44564.

Full text
Abstract:
In this study, we have explored the combination of a novel Purine Nucleoside Phosphorylase mediated Gene-Directed Enzyme Prodrug Therapy (PNP-GDEPT) with chemotherapeutics, Taxotere and/or Carboplatin to target prostate and ovarian cancer (PC & OC). PNP converts the prodrug (Fludarabine-phosphate) to a toxic purine, 2-fluoroadenine (2FA) that inhibits RNA/DNA synthesis. Taxotere is active against late stage PC whilst carboplatin is first line therapy for OC. Neither modality is adequately effective. We expect that a combination will target heterogeneity via cytotoxicity to diverse cancer cell
APA, Harvard, Vancouver, ISO, and other styles
32

Gréen, Henrik. "Pharmacogenetic studies of paclitaxel in ovarian cancer : focus on interindividual differences in pharmacodynamics and pharmacokinetics /." Linköping : Univ, 2007. http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-8134.

Full text
APA, Harvard, Vancouver, ISO, and other styles
33

Palinska-Rudzka, Karolina. "Effects of chemotherapy upon fertility amongst women of reproductive age, using AMH as a marker of ovarian reserve." Thesis, University of Warwick, 2015. http://wrap.warwick.ac.uk/77838/.

Full text
Abstract:
Nowadays, early detection of cancer and improving survival rates mean that more young women diagnosed with cancer have a normal life expectancy. For many of them the ability to conceive after successful treatment is one of their prime concerns. This dissertation evaluated the adverse effects upon fertility of some of the most common chemotherapeutic regimens used for cancers affecting women of reproductive age. Serial serum anti-Müllerian hormone(AMH) measurements were used to assess ovarian function in female patients with breast cancer or lymphoma before chemotherapy and compared longitudina
APA, Harvard, Vancouver, ISO, and other styles
34

Moraes, Alan Cesar Nunes de. "Efeitos tardios no tecido ovariano de ratas Wistar após tratamento com Docetaxel e Ciclofosfamida." Universidade do Estado do Rio de Janeiro, 2015. http://www.bdtd.uerj.br/tde_busca/arquivo.php?codArquivo=9500.

Full text
Abstract:
O câncer de mama (CM) é o segundo tipo de câncer mais comum no mundo. Sabe-se que a maior incidência de CM ocorre nas mulheres pós-menopausa, entretanto é crescente o número de mulheres jovens acometidas por esta doença. O tratamento do CM pode incluir: quimioterapia, radioterapia e/ou hormonioterapia. A quimioterapia, por se ser um tratamento sistêmico, pode causar importantes efeitos colaterais, entre eles a falência ovariana induzida por quimioterapia (FOIQ). As principais consequências da FOIQ são a infertilidade, além de complicações tardias relacionadas à diminuição do estrogênio, como a
APA, Harvard, Vancouver, ISO, and other styles
35

FERRAIOLI, DOMENICO. "Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer." Doctoral thesis, Università degli studi di Genova, 2019. http://hdl.handle.net/11567/989355.

Full text
Abstract:
Abstract in English Schlafen 11 (SLFN11) is a putative DNA/RNA helicase, first described for its role in thymocyte development and differentiation in mouse models [1]. SLFN11 is part of a family of proteins with various degree of homology across species, but intriguingly being consistently present only in vertebrates and especially in mammals. Recently the role of this putative DNA/RNA helicase, SLFN11, was causal association with sensitivity to DNA damaging agents, such as platinum salts, topoisomerase I and II inhibitors, and other alkylators in the NCI-60 panel of cancer cell lines.13 In th
APA, Harvard, Vancouver, ISO, and other styles
36

Nielsen, Frederick A. "Harnessing Macrophage Polarization for Platinum-based Immunochemotherapy." Kent State University / OhioLINK, 2018. http://rave.ohiolink.edu/etdc/view?acc_num=kent1525778398029577.

Full text
APA, Harvard, Vancouver, ISO, and other styles
37

Zanjirband, Maryam. "The genomic and functional status of TP53 in ovarian cancer : biomarker for chemotherapy outcome and determinant of response to MDM2 inhibitors." Thesis, University of Newcastle upon Tyne, 2017. http://hdl.handle.net/10443/3831.

Full text
Abstract:
Background: Mutation and loss of TP53 function is one of the most frequent genetic abnormalities in ovarian cancer. TP53 genomic and functional status have been shown to provide potentially prognostic and predictive value in ovarian cancer; however, the results are controversial and evaluation in the context of a controlled clinical trial with single agent treatment have been lacking. Reactivation of p53 using MDM2-p53 antagonists is a promising therapeutic target for most patients with type I epithelial ovarian cancer and those left from type II harbouring wild-type TP53. BRCA1/2 mutations ar
APA, Harvard, Vancouver, ISO, and other styles
38

Hoarau, Jessica. "Halfway Between 2D Models and Animal Models : a New Multicellular 3D Spheroid Model Organized to Study Tumor-Endothelium Interactions in Ovarian Cancer." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS111.

Full text
Abstract:
Le cancer de l'ovaire (CO) est la cinquième cause de décès chez les femmes qui se caractérise par son diagnostic tardif (stades FIGO III et IV) et par l’importance de ses métastases abdominales souvent observées au moment du diagnostic. Le traitement repose sur une chirurgie cytoréductive complète associée à une chimiothérapie. Malheureusement, parmi les patientes ayant une rémission clinique complète après la fin du traitement initial, 60% des personnes atteintes d'un cancer épithélial de l'ovaire (CEO) à un stade avancé rechuteront dans les cinq ans.L'importance de la néo-angiogenèse dans le
APA, Harvard, Vancouver, ISO, and other styles
39

Nagesetti, Abhignyan. "The Effect of Hyperthermia on Doxorubicin Therapy and Nanoparticle Penetration in Multicellular Ovarian Cancer Spheroids." FIU Digital Commons, 2017. http://digitalcommons.fiu.edu/etd/3183.

Full text
Abstract:
The efficient treatment of cancer with chemotherapy is challenged by the limited penetration of drugs into the tumor. Nanoparticles (10 – 100 nanometers) have emerged as a logical choice to specifically deliver chemotherapeutics to tumors, however, their transport into the tumor is also impeded owing to their bigger size compared to free drug moieties. Currently, monolayer cell cultures, as models for drug testing, cannot recapitulate the structural and functional complexity of in-vivo tumors. Furthermore, strategies to improve drug distribution in tumor tissues are also required. In this stud
APA, Harvard, Vancouver, ISO, and other styles
40

Ferraioli, Domenico. "Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer." Electronic Thesis or Diss., Lyon, 2019. http://www.theses.fr/2019LYSE1324.

Full text
Abstract:
Schlafen 11 (SLFN11) est une ADN/ARN hélicase décrite pour la première fois pour son rôle dans le développement et la différenciation des thymocytes chez la souris. Elle fait partie d'une famille de protéines présentant divers degrés d'homologie entre les espèces, mais qu’est présente de façon constante chez les mammifères. Le rôle de cette ADN/ARN hélicase, SLFN11, a été associé de façon causale à la sensibilité de réponse aux différents agents alkylants (agents endommageant l'ADN, les inhibiteurs de topo-isomérase I et II) dans le NCI-60. Dans la première étude, nous avons développé un proto
APA, Harvard, Vancouver, ISO, and other styles
41

Ferraioli, Domenico. "Assessment and relevance of the putative DNA/RNA helicase Schlafen-11 in ovarian and breast cancer." Thesis, Lyon, 2019. http://www.theses.fr/2019LYSE1324/document.

Full text
Abstract:
Schlafen 11 (SLFN11) est une ADN/ARN hélicase décrite pour la première fois pour son rôle dans le développement et la différenciation des thymocytes chez la souris. Elle fait partie d'une famille de protéines présentant divers degrés d'homologie entre les espèces, mais qu’est présente de façon constante chez les mammifères. Le rôle de cette ADN/ARN hélicase, SLFN11, a été associé de façon causale à la sensibilité de réponse aux différents agents alkylants (agents endommageant l'ADN, les inhibiteurs de topo-isomérase I et II) dans le NCI-60. Dans la première étude, nous avons développé un proto
APA, Harvard, Vancouver, ISO, and other styles
42

Adams, Nyssa R. "Protein targets of two novel anticancer agents." Ohio University Honors Tutorial College / OhioLINK, 2011. http://rave.ohiolink.edu/etdc/view?acc_num=ouhonors1311102442.

Full text
APA, Harvard, Vancouver, ISO, and other styles
43

Paudel, Iru. "Sab Concentration Determines the Chemotherapeutic Efficacy in Gynecological Cancer." FIU Digital Commons, 2018. https://digitalcommons.fiu.edu/etd/3707.

Full text
Abstract:
The American Cancer Society predicts there will be 110,070 new cases and 32,120 deaths due to gynecological malignancies in 2018. A major contributing factor to the high mortality associated with gynecological cancers is the recurrence of treatment-resistant tumors. Ovarian cancer (OC) remains the most lethal gynecological malignancy, yet the mechanisms responsible for regulating tumor resistance and vulnerability are largely unknown or undruggable. Therefore, the goal of this research is to identify mechanisms responsible for therapeutic resistance in gynecological cancers and discover innova
APA, Harvard, Vancouver, ISO, and other styles
44

Bedoschi, Giuliano Marchetti. "Caracterização do impacto dos regimes quimioterápicos na reserva ovariana de pacientes com câncer de mama." Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/17/17145/tde-01022019-104131/.

Full text
Abstract:
Parte das mulheres com câncer de mama na menacme gostariam de tentar preservar sua fertilidade após o tratamento oncológico. Entretanto, as informações disponíveis sobre a extensão do dano aos ovários após o tratamento quimioterápico são insuficientes para estimar o risco de comprometimento da reserva ovariana. Dessa forma, como objetivo primário deste estudo propusemos caracterizar o impacto dos regimes quimioterápicos mais comumente utilizados no tratamento do câncer de mama em mulheres na menacme sobre a reserva ovariana avaliada por meio da aferição das concentrações séricas de hormônio an
APA, Harvard, Vancouver, ISO, and other styles
45

Mano, Max Senna. "Topoisomerase ll-a e Her-2 em tumores malignos de mama e de ovário." reponame:Biblioteca Digital de Teses e Dissertações da UFRGS, 2006. http://hdl.handle.net/10183/8538.

Full text
Abstract:
Introdução. O receptor epidérmico humano 2 (Her-2) e a topoisomerase-IIα (T2A) são dois marcadores biológicos importantes, ambos tendo um valor prognóstico e preditivo potencial em pacientes com tumores sólidos. A amplificação dos genes Her- 2 e T2A são eventos independentes, embora o último seja mais frequente em tumores com amplificação do Her-2 (34-90%), do que em tumores sem amplificação do Her-2 (5-10%). Existe uma melhor correlação entre amplificação e superexpressão do Her-2 no câncer de mama (CM) do que em outros tumores. No entanto, no CM, a correlação entre amplificação e superexpres
APA, Harvard, Vancouver, ISO, and other styles
46

Fazel, Afchine. "Particules chargées en anticancéreux : traitement local des cancers gynécologiques." Thesis, Paris 11, 2012. http://www.theses.fr/2012PA114866.

Full text
Abstract:
La chimiothérapie systémique par voie intraveineuse, essentiellement réservée aux cancers avancés, n'est pas ciblée sur la tumeur, il est très difficile d’atteindre des niveaux thérapeutiques en intra tumoral, et ses effets secondaires et sa toxicité sont doses-limitantes.La chimiothérapie localisée pourrait permettre :1) la stabilisation des molécules médicamenteuses incorporées une seule administration médicamenteuse,2) une libération prolongée et contrôlée du médicament pour assurer une diffusion adéquate et l'absorption par les cellules cancéreuses sur plusieurs cycles de division cellulai
APA, Harvard, Vancouver, ISO, and other styles
47

Bakrin, Naoual. "Évaluation de la chimiohyperthermie intrapéritonéale dans le traitement du cancer épithélial de l’ovaire." Thesis, Lyon 1, 2014. http://www.theses.fr/2014LYO10363.

Full text
Abstract:
L'association chirurgie de cytoréduction et chimiohyperthermie intrapéritonéale (CHIP) n'est pas un traitement reconnu de la carcinose péritonéale (CP) d'origine ovarienne. En France et dans le monde, des centres experts dans la prise en charge des CP ont proposé ce traitement combiné à des patientes avec un carcinome épithélial de l'ovaire (CEO). Le but de ce travail était, au travers d'études expérimentales et cliniques, de rapporter l'expérience des centres français en élaborant un registre national de patientes traitées pour un carcinome épithélial de l'ovaire par CRS et CHIP et d'explique
APA, Harvard, Vancouver, ISO, and other styles
48

Freyer, Luisa [Verfasser], and Ralf [Akademischer Betreuer] Schmidmaier. "The addition of the novel heparan sulfate (HS) mimetic PG545 to standard chemotherapy shows promising efficacy in the treatment of ovarian cancer in vitro and in vivo / Luisa Freyer ; Betreuer: Ralf Schmidmaier." München : Universitätsbibliothek der Ludwig-Maximilians-Universität, 2018. http://d-nb.info/1161670777/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
49

Schmitt, Wolfgang Daniel. "Expression und Regulation der MAPK-Phosphatasen im Ovarialkarzinom." Doctoral thesis, [S.l.] : [s.n.], 2005. http://deposit.ddb.de/cgi-bin/dokserv?idn=974669334.

Full text
APA, Harvard, Vancouver, ISO, and other styles
50

Liu, Jin. "Contribution du couple neurotensine et son récepteur de haute affinité dans la réponse à la chimiothérapie dans le cancer de l'ovaire." Thesis, Paris 6, 2017. http://www.theses.fr/2017PA066080/document.

Full text
Abstract:
Le cancer de l'ovaire est la huitième cause de décès par cancer chez la femme dans le monde. Le traitement proposant la combinaison carboplatine-paclitaxel donne un taux de réponse complet dans 40 à 60 % des cas. Cependant, plus de 90 % des patientes récidive après 2 ans. Il a été montré que le complexe de neurotensine (NTS) et son récepteur à haute affinité 1 (NTSR1) favorise la progression du cancer par prolifération, migration, invasion et néoangiogenèse in vitro et/ou in vivo dans de nombreux cancers. A ce jour, le rôle du complexe NTS/NTSR1 dans la réponse à la chimiothérapie n'a pas été
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the bibliographies on the topic 'Ovarian cancer, chemotherapy' for other source types:
Journal articles Books
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography